文献速递妇科

卵巢癌患者对二线铂类治疗的反应率挑战铂耐药临床定义

Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
PubMed 文献 · Gynecol Oncol · 2018-05-26

该研究纳入澳大利亚卵巢癌研究(AOCS)中接受铂类一线化疗的高级别上皮性卵巢癌患者,比较按6个月阈值定义为「铂耐药」者在首次复发时接受含铂或非铂化疗的反应率与生存。结果显示含铂化疗的CA-125反应率显著高于非铂化疗(51% vs 21%,P < 0.001);无铂间期(PFI)3-6个月者含铂组OS2显著更长。

要点

  • 按6个月阈值定义的「铂耐药」患者中,含铂二线化疗CA-125反应率51% vs 非铂21%(P < 0.001)。
  • PFI 3-6个月者含铂组OS2中位17.67个月 vs 非铂组10.62个月(P = 0.022)。
  • PFI <3个月者二线治疗类型间反应与生存无显著差异。

核心结论

  • 研究结果进一步质疑以6个月PFI作为后续治疗决策的任意阈值。
  • 部分被认为「铂耐药」的患者仍从含铂化疗中获得临床获益。
  • 临床实践中需要铂敏感性的生物标志物来识别可能从铂类再治疗中获益的患者。

研究设计与样本

  • 纳入澳大利亚卵巢癌研究(AOCS)中所有组织学类型、接受铂类一线化疗的高级别上皮性卵巢癌(含输卵管癌和腹膜癌)患者。
  • 按6个月阈值分类为铂耐药者共341例,其中243例(71%)在复发时接受化疗。
  • 比较二线含铂与非铂化疗的反应率、总生存(OS)及首次进展治疗后生存(OS2),并在高级别浆液性肿瘤中单独分析。

主要发现

  • 含铂化疗的CA-125反应率显著高于非铂化疗(51% vs 21%,P < 0.001)。
  • PFI 3-6个月患者中,含铂组OS2中位17.67个月(95% CI: 14.79-20.75)vs 非铂组10.62个月(95% CI: 8.02-12.72),P = 0.022。
  • 限制于高级别浆液性组织学患者时,上述模式相似。
  • PFI <3个月患者中,二线治疗类型间的反应或生存无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to compare response rates and survival in women with "platinum resistant" epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. METHODS: Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included. Response to second-line chemotherapy, overall survival (OS) and survival after treatment for first progression (OS2) were determined in all histologies and separately in women with high-grade serous tumors. RESULTS: Of the 341 patients classified as platinum-resistant by the 6-month threshold, 243 (71%) were treated with chemotherapy at relapse. CA-125 response rates to platinum-based chemotherapy were significantly higher compared to non‑platinum chemotherapy (51% vs 21%, P < 0.001). Among patients with a platinum-free interval (PFI) of 3-6 months, OS2 in patients treated with platinum was significantly longer compared to individuals receiving non‑platinum-based treatment (median 17.67 months, 95% CI: 14.79-20.75 vs. 10.62 months, 95% CI: 8.02-12.72, P = 0.022). The patterns were similar when restricted to patients with high-grade serous histology. In patients with PFI <3 months, there was no significant difference in response or survival according to type of second-line treatment. CONCLUSIONS: Our findings further question the use of a 6-month PFI as an arbitrary threshold for subsequent treatment decision-making. Some patients considered "platinum resistant" still derive clinical benefit from platinum-based chemotherapy. Biomarkers of platinum sensitivity are needed in clinical practice to identify potential responders who should be offered re-treatment with platinum.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Lindemann K, Gao B, Mapagu C, et al. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecol Oncol. 2018. PMID: 29807697. doi:10.1016/j.ygyno.2018.05.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。